{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:07:34Z","timestamp":1792192054556,"version":"4.4.0"},"reference-count":159,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Grant No. 82072854"],"award-info":[{"award-number":["Grant No. 82072854"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015806","name":"Project for Key Medicine Discipline Construction of Guangzhou Municipality","doi-asserted-by":"publisher","award":["Grant No. 2021-2023-17"],"award-info":[{"award-number":["Grant No. 2021-2023-17"]}],"id":[{"id":"10.13039\/501100015806","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Super enhancers are a unique class of enhancers that possess a distinct structure and mechanism, which enable them to exhibit stronger gene transcription regulatory function than classical enhancers, thereby regulating cellular activities. In tumor samples, super enhancers have been identified as crucial players in the development and progression of tumor cells, opening up new avenues for cancer research and treatment. This review provides a concise overview of various models regarding super enhancer assembly and activation, examining the mechanisms through which tumor cells acquire or activate these enhancers and regulate carcinogenic transcription programs. Furthermore, we discuss the current landscape and challenges in developing cancer therapeutic drugs that target super enhancers.<\/jats:p>","DOI":"10.1186\/s12967-025-06098-x","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T13:31:48Z","timestamp":1737466308000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Super-enhancers in tumors: unraveling recent advances in their role in Oncogenesis and the emergence of targeted therapies"],"prefix":"10.1186","volume":"23","author":[{"given":"Yumeng","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baixue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongjin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3226-8127","authenticated-orcid":false,"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"issue":"5","key":"6098_CR1","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135(5):584\u201390.","journal-title":"Chin Med J"},{"issue":"6","key":"6098_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.molmed.2012.04.006","volume":"18","author":"I Bozic","year":"2012","unstructured":"Bozic I, Allen B, Nowak MA. Dynamics of targeted cancer therapy. Trends Mol Med. 2012;18(6):311\u20136.","journal-title":"Trends Mol Med"},{"issue":"2","key":"6098_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40290-020-00326-z","volume":"34","author":"SK Nakhoda","year":"2020","unstructured":"Nakhoda SK, Olszanski AJ. Addressing recent failures in Immuno-Oncology trials to Guide Novel Immunotherapeutic Treatment Strategies. Pharm Med. 2020;34(2):83\u201391.","journal-title":"Pharm Med"},{"key":"6098_CR4","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.3389\/fonc.2020.01290","volume":"10","author":"R Bai","year":"2020","unstructured":"Bai R, Chen N, Li L, Du N, Bai L, Lv Z, et al. Mechanisms of Cancer Resistance to Immunotherapy. Front Oncol. 2020;10:1290.","journal-title":"Front Oncol"},{"issue":"5","key":"6098_CR5","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"4","key":"6098_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","volume":"168","author":"JE Bradner","year":"2017","unstructured":"Bradner JE, Hnisz D, Young RA. Transcriptional addiction in Cancer. Cell. 2017;168(4):629\u201343.","journal-title":"Cell"},{"issue":"6","key":"6098_CR7","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.cell.2013.02.014","volume":"152","author":"TI Lee","year":"2013","unstructured":"Lee TI, Young RA. Transcriptional regulation and its misregulation in disease. Cell. 2013;152(6):1237\u201351.","journal-title":"Cell"},{"issue":"3","key":"6098_CR8","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1101\/gad.255182.114","volume":"29","author":"MA Morgan","year":"2015","unstructured":"Morgan MA, Shilatifard A. Chromatin signatures of cancer. Genes Dev. 2015;29(3):238\u201349.","journal-title":"Genes Dev"},{"issue":"6","key":"6098_CR9","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.tig.2012.02.008","volume":"28","author":"C Buecker","year":"2012","unstructured":"Buecker C, Wysocka J. Enhancers as information integration hubs in development: lessons from genomics. Trends Genet. 2012;28(6):276\u201384.","journal-title":"Trends Genet"},{"issue":"9","key":"6098_CR10","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nrg3207","volume":"13","author":"F Spitz","year":"2012","unstructured":"Spitz F, Furlong EE. Transcription factors: from enhancer binding to developmental control. Nat Rev Genet. 2012;13(9):613\u201326.","journal-title":"Nat Rev Genet"},{"issue":"8","key":"6098_CR11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nrc.2016.62","volume":"16","author":"I Sur","year":"2016","unstructured":"Sur I, Taipale J. The role of enhancers in cancer. Nat Rev Cancer. 2016;16(8):483\u201393.","journal-title":"Nat Rev Cancer"},{"issue":"2 Pt 1","key":"6098_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0092-8674(81)90413-X","volume":"27","author":"J Banerji","year":"1981","unstructured":"Banerji J, Rusconi S, Schaffner W. Expression of a beta-globin gene is enhanced by remote SV40 DNA sequences. Cell. 1981;27(2 Pt 1):299\u2013308.","journal-title":"Cell"},{"issue":"5","key":"6098_CR13","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.molcel.2013.01.038","volume":"49","author":"E Calo","year":"2013","unstructured":"Calo E, Wysocka J. Modification of enhancer chromatin: what, how, and why? Mol Cell. 2013;49(5):825\u201337.","journal-title":"Mol Cell"},{"issue":"2","key":"6098_CR14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.cell.2016.02.064","volume":"165","author":"H Shen","year":"2016","unstructured":"Shen H, Xu W, Guo R, Rong B, Gu L, Wang Z, et al. Suppression of enhancer overactivation by a RACK7-Histone demethylase complex. Cell. 2016;165(2):331\u201342.","journal-title":"Cell"},{"issue":"4","key":"6098_CR15","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","volume":"155","author":"D Hnisz","year":"2013","unstructured":"Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-Andr\u00e9 V, Sigova AA, et al. Super-enhancers in the control of cell identity and disease. Cell. 2013;155(4):934\u201347.","journal-title":"Cell"},{"issue":"2","key":"6098_CR16","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","volume":"153","author":"J Lov\u00e9n","year":"2013","unstructured":"Lov\u00e9n J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153(2):320\u201334.","journal-title":"Cell"},{"issue":"6","key":"6098_CR17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41419-023-05892-z","volume":"14","author":"Z Chen","year":"2023","unstructured":"Chen Z, Tian D, Chen X, Cheng M, Xie H, Zhao J, et al. Super-enhancer-driven lncRNA LIMD1-AS1 activated by CDK7 promotes glioma progression. Cell Death Dis. 2023;14(6):383.","journal-title":"Cell Death Dis"},{"issue":"1","key":"6098_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12943-023-01762-6","volume":"22","author":"E Thieme","year":"2023","unstructured":"Thieme E, Bruss N, Sun D, Dominguez EC, Coleman D, Liu T, et al. CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma. Mol Cancer. 2023;22(1):64.","journal-title":"Mol Cancer"},{"issue":"2","key":"6098_CR19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","volume":"153","author":"WA Whyte","year":"2013","unstructured":"Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell. 2013;153(2):307\u201319.","journal-title":"Cell"},{"issue":"4","key":"6098_CR20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.trecan.2017.03.006","volume":"3","author":"S Sengupta","year":"2017","unstructured":"Sengupta S, George RE. Super-enhancer-driven Transcriptional dependencies in Cancer. Trends cancer. 2017;3(4):269\u201381.","journal-title":"Trends cancer"},{"issue":"2","key":"6098_CR21","first-page":"216","volume":"84","author":"S Yoshino","year":"2022","unstructured":"Yoshino S, Suzuki HI. The molecular understanding of super-enhancer dysregulation in cancer. Nagoya J Med Sci. 2022;84(2):216\u201329.","journal-title":"Nagoya J Med Sci"},{"issue":"6","key":"6098_CR22","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.ccell.2019.10.004","volume":"36","author":"Y Huang","year":"2019","unstructured":"Huang Y, Mouttet B, Warnatz HJ, Risch T, Rietmann F, Frommelt F, et al. The leukemogenic TCF3-HLF complex rewires Enhancers Driving Cellular Identity and Self-Renewal conferring EP300 vulnerability. Cancer Cell. 2019;36(6):630\u2013e449.","journal-title":"Cancer Cell"},{"issue":"3","key":"6098_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ccell.2017.02.006","volume":"31","author":"C Thirant","year":"2017","unstructured":"Thirant C, Ignacimouttou C, Lopez CK, Diop M, Le Mou\u00ebl L, Thiollier C, et al. ETO2-GLIS2 hijacks transcriptional complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia. Cancer Cell. 2017;31(3):452\u201365.","journal-title":"Cancer Cell"},{"issue":"2","key":"6098_CR24","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41594-020-00550-w","volume":"28","author":"S Terlecki-Zaniewicz","year":"2021","unstructured":"Terlecki-Zaniewicz S, Humer T, Eder T, Schmoellerl J, Heyes E, Manhart G, et al. Biomolecular condensation of NUP98 fusion proteins drives leukemogenic gene expression. Nat Struct Mol Biol. 2021;28(2):190\u2013201.","journal-title":"Nat Struct Mol Biol"},{"issue":"7868","key":"6098_CR25","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41586-021-03662-5","volume":"595","author":"JH Ahn","year":"2021","unstructured":"Ahn JH, Davis ES, Daugird TA, Zhao S, Quiroga IY, Uryu H, et al. Phase separation drives aberrant chromatin looping and cancer development. Nature. 2021;595(7868):591\u20135.","journal-title":"Nature"},{"issue":"1","key":"6098_CR26","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.cell.2018.05.048","volume":"174","author":"JA Pulikkan","year":"2018","unstructured":"Pulikkan JA, Hegde M, Ahmad HM, Belaghzal H, Illendula A, Yu J, et al. CBF\u03b2-SMMHC inhibition triggers apoptosis by disrupting MYC Chromatin Dynamics in Acute myeloid leukemia. Cell. 2018;174(1):172\u2013e8621.","journal-title":"Cell"},{"issue":"21","key":"6098_CR27","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1182\/blood.2020007747","volume":"136","author":"T Zhen","year":"2020","unstructured":"Zhen T, Cao Y, Ren G, Zhao L, Hyde RK, Lopez G, et al. RUNX1 and CBF\u03b2-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development. Blood. 2020;136(21):2373\u201385.","journal-title":"Blood"},{"issue":"4","key":"6098_CR28","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.ccell.2018.08.018","volume":"34","author":"Y Sun","year":"2018","unstructured":"Sun Y, Zhou B, Mao F, Xu J, Miao H, Zou Z, et al. HOXA9 reprograms the enhancer Landscape to Promote Leukemogenesis. Cancer Cell. 2018;34(4):643\u2013e585.","journal-title":"Cancer Cell"},{"issue":"1","key":"6098_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1182\/blood.2019004586","volume":"137","author":"S Yoshino","year":"2021","unstructured":"Yoshino S, Yokoyama T, Sunami Y, Takahara T, Nakamura A, Yamazaki Y, et al. Trib1 promotes acute myeloid leukemia progression by modulating the transcriptional programs of Hoxa9. Blood. 2021;137(1):75\u201388.","journal-title":"Blood"},{"issue":"2","key":"6098_CR30","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ccell.2018.07.007","volume":"34","author":"M Vanden Bempt","year":"2018","unstructured":"Vanden Bempt M, Demeyer S, Broux M, De Bie J, Bornschein S, Mentens N, et al. Cooperative enhancer activation by TLX1 and STAT5 drives development of NUP214-ABL1\/TLX1-Positive T cell Acute Lymphoblastic Leukemia. Cancer Cell. 2018;34(2):271\u2013. \u2013\u200985.e7.","journal-title":"Cancer Cell"},{"issue":"3","key":"6098_CR31","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1158\/2159-8290.CD-16-1417","volume":"7","author":"J Zhang","year":"2017","unstructured":"Zhang J, Vlasevska S, Wells VA, Nataraj S, Holmes AB, Duval R, et al. The CREBBP acetyltransferase is a haploinsufficient tumor suppressor in B-cell lymphoma. Cancer Discov. 2017;7(3):322\u201337.","journal-title":"Cancer Discov"},{"issue":"3","key":"6098_CR32","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ccell.2018.08.006","volume":"34","author":"P Brescia","year":"2018","unstructured":"Brescia P, Schneider C, Holmes AB, Shen Q, Hussein S, Pasqualucci L, et al. MEF2B instructs Germinal Center Development and acts as an Oncogene in B Cell Lymphomagenesis. Cancer Cell. 2018;34(3):453\u2013e659.","journal-title":"Cancer Cell"},{"key":"6098_CR33","doi-asserted-by":"crossref","unstructured":"Wang C, Jiang S, Zhang L, Li D, Liang J, Narita Y et al. TAF Family proteins and MEF2C are essential for Epstein-Barr Virus Super-enhancer Activity. J Virol. 2019;93(16).","DOI":"10.1128\/JVI.00513-19"},{"key":"6098_CR34","doi-asserted-by":"crossref","unstructured":"Manzano M, G\u00fcnther T, Ju H, Nicholas J, Bartom ET, Grundhoff A et al. Kaposi\u2019s Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma. mBio. 2020;11(4).","DOI":"10.1128\/mBio.01457-20"},{"issue":"2","key":"6098_CR35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cell.2014.02.019","volume":"157","author":"S Gr\u00f6schel","year":"2014","unstructured":"Gr\u00f6schel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BAM, Erpelinck C, et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell. 2014;157(2):369\u201381.","journal-title":"Cell"},{"issue":"4","key":"6098_CR36","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccr.2014.02.008","volume":"25","author":"H Yamazaki","year":"2014","unstructured":"Yamazaki H, Suzuki M, Otsuki A, Shimizu R, Bresnick EH, Engel JD, et al. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell. 2014;25(4):415\u201327.","journal-title":"Cancer Cell"},{"issue":"7510","key":"6098_CR37","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nature13379","volume":"511","author":"PA Northcott","year":"2014","unstructured":"Northcott PA, Lee C, Zichner T, St\u00fctz AM, Erkek S, Kawauchi D, et al. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature. 2014;511(7510):428\u201334.","journal-title":"Nature"},{"issue":"3","key":"6098_CR38","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/ng.3502","volume":"48","author":"Y Drier","year":"2016","unstructured":"Drier Y, Cotton MJ, Williamson KE, Gillespie SM, Ryan RJ, Kluk MJ, et al. An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. Nat Genet. 2016;48(3):265\u201372.","journal-title":"Nat Genet"},{"issue":"1","key":"6098_CR39","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13059-020-02076-2","volume":"21","author":"JW Yun","year":"2020","unstructured":"Yun JW, Yang L, Park HY, Lee CW, Cha H, Shin HT, et al. Dysregulation of cancer genes by recurrent intergenic fusions. Genome Biol. 2020;21(1):166.","journal-title":"Genome Biol"},{"issue":"10","key":"6098_CR40","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1158\/2159-8290.CD-15-0370","volume":"5","author":"RJ Ryan","year":"2015","unstructured":"Ryan RJ, Drier Y, Whitton H, Cotton MJ, Kaur J, Issner R, et al. Detection of enhancer-Associated Rearrangements reveals mechanisms of Oncogene Dysregulation in B-cell lymphoma. Cancer Discov. 2015;5(10):1058\u201371.","journal-title":"Cancer Discov"},{"issue":"6215","key":"6098_CR41","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1126\/science.1259037","volume":"346","author":"MR Mansour","year":"2014","unstructured":"Mansour MR, Abraham BJ, Anders L, Berezovskaya A, Gutierrez A, Durbin AD, et al. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Sci (New York NY). 2014;346(6215):1373\u20137.","journal-title":"Sci (New York NY)"},{"issue":"8","key":"6098_CR42","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41568-021-00371-z","volume":"21","author":"K Elliott","year":"2021","unstructured":"Elliott K, Larsson E. Non-coding driver mutations in human cancer. Nat Rev Cancer. 2021;21(8):500\u20139.","journal-title":"Nat Rev Cancer"},{"issue":"6280","key":"6098_CR43","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1126\/science.aad9024","volume":"351","author":"D Hnisz","year":"2016","unstructured":"Hnisz D, Weintraub AS, Day DS, Valton AL, Bak RO, Li CH, et al. Activation of proto-oncogenes by disruption of chromosome neighborhoods. Sci (New York NY). 2016;351(6280):1454\u20138.","journal-title":"Sci (New York NY)"},{"issue":"5","key":"6098_CR44","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1158\/2159-8290.CD-19-1128","volume":"10","author":"K Li","year":"2020","unstructured":"Li K, Zhang Y, Liu X, Liu Y, Gu Z, Cao H, et al. Noncoding variants connect enhancer dysregulation with nuclear receptor signaling in hematopoietic malignancies. Cancer Discov. 2020;10(5):724\u201345.","journal-title":"Cancer Discov"},{"issue":"7314","key":"6098_CR45","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/nature09380","volume":"467","author":"MH Kagey","year":"2010","unstructured":"Kagey MH, Newman JJ, Bilodeau S, Zhan Y, Orlando DA, van Berkum NL, et al. Mediator and cohesin connect gene expression and chromatin architecture. Nature. 2010;467(7314):430\u20135.","journal-title":"Nature"},{"issue":"1","key":"6098_CR46","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cell.2014.02.009","volume":"157","author":"M Levine","year":"2014","unstructured":"Levine M, Cattoglio C, Tjian R. Looping back to Leap forward: transcription enters a new era. Cell. 2014;157(1):13\u201325.","journal-title":"Cell"},{"issue":"6","key":"6098_CR47","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.cell.2012.03.051","volume":"149","author":"W Deng","year":"2012","unstructured":"Deng W, Lee J, Wang H, Miller J, Reik A, Gregory PD, et al. Controlling long-range genomic interactions at a native locus by targeted tethering of a looping factor. Cell. 2012;149(6):1233\u201344.","journal-title":"Cell"},{"issue":"9","key":"6098_CR48","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1038\/s41588-018-0175-z","volume":"50","author":"H Chen","year":"2018","unstructured":"Chen H, Levo M, Barinov L, Fujioka M, Jaynes JB, Gregor T. Dynamic interplay between enhancer-promoter topology and gene activity. Nat Genet. 2018;50(9):1296\u2013303.","journal-title":"Nat Genet"},{"issue":"7","key":"6098_CR49","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.cell.2017.11.008","volume":"171","author":"AS Weintraub","year":"2017","unstructured":"Weintraub AS, Li CH, Zamudio AV, Sigova AA, Hannett NM, Day DS, et al. YY1 is a Structural Regulator of enhancer-promoter loops. Cell. 2017;171(7):1573\u2013e8828.","journal-title":"Cell"},{"issue":"7455","key":"6098_CR50","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/nature12210","volume":"498","author":"W Li","year":"2013","unstructured":"Li W, Notani D, Ma Q, Tanasa B, Nunez E, Chen AY, et al. Functional roles of enhancer RNAs for oestrogen-dependent transcriptional activation. Nature. 2013;498(7455):516\u201320.","journal-title":"Nature"},{"issue":"1","key":"6098_CR51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cell.2017.02.007","volume":"169","author":"D Hnisz","year":"2017","unstructured":"Hnisz D, Shrinivas K, Young RA, Chakraborty AK, Sharp PA. A phase separation model for Transcriptional Control. Cell. 2017;169(1):13\u201323.","journal-title":"Cell"},{"issue":"5","key":"6098_CR52","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.cell.2016.05.026","volume":"165","author":"LP Bergeron-Sandoval","year":"2016","unstructured":"Bergeron-Sandoval LP, Safaee N, Michnick SW. Mechanisms and consequences of Macromolecular phase separation. Cell. 2016;165(5):1067\u201379.","journal-title":"Cell"},{"issue":"5935","key":"6098_CR53","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1126\/science.1172046","volume":"324","author":"CP Brangwynne","year":"2009","unstructured":"Brangwynne CP, Eckmann CR, Courson DS, Rybarska A, Hoege C, Gharakhani J, et al. Germline P granules are liquid droplets that localize by controlled dissolution\/condensation. Sci (New York NY). 2009;324(5935):1729\u201332.","journal-title":"Sci (New York NY)"},{"issue":"1","key":"6098_CR54","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cell.2015.09.015","volume":"163","author":"A Molliex","year":"2015","unstructured":"Molliex A, Temirov J, Lee J, Coughlin M, Kanagaraj AP, Kim HJ, et al. Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell. 2015;163(1):123\u201333.","journal-title":"Cell"},{"issue":"2","key":"6098_CR55","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.molcel.2014.08.024","volume":"56","author":"JD Brown","year":"2014","unstructured":"Brown JD, Lin CY, Duan Q, Griffin G, Federation A, Paranal RM, et al. NF-\u03baB directs dynamic super enhancer formation in inflammation and atherogenesis. Mol Cell. 2014;56(2):219\u201331.","journal-title":"Mol Cell"},{"issue":"2","key":"6098_CR56","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.molcel.2015.02.014","volume":"58","author":"D Hnisz","year":"2015","unstructured":"Hnisz D, Schuijers J, Lin CY, Weintraub AS, Abraham BJ, Lee TI, et al. Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. Mol Cell. 2015;58(2):362\u201370.","journal-title":"Mol Cell"},{"issue":"8","key":"6098_CR57","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/ng.3606","volume":"48","author":"HY Shin","year":"2016","unstructured":"Shin HY, Willi M, HyunYoo K, Zeng X, Wang C, Metser G, et al. Hierarchy within the mammary STAT5-driven Wap super-enhancer. Nat Genet. 2016;48(8):904\u201311.","journal-title":"Nat Genet"},{"issue":"6","key":"6098_CR58","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ccr.2013.11.003","volume":"24","author":"B Chapuy","year":"2013","unstructured":"Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MG, Qi J, et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell. 2013;24(6):777\u201390.","journal-title":"Cancer Cell"},{"issue":"5","key":"6098_CR59","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.cell.2014.10.024","volume":"159","author":"E Chipumuro","year":"2014","unstructured":"Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell. 2014;159(5):1126\u201339.","journal-title":"Cell"},{"issue":"7511","key":"6098_CR60","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nature13393","volume":"511","author":"N Kwiatkowski","year":"2014","unstructured":"Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014;511(7511):616\u201320.","journal-title":"Nature"},{"issue":"1","key":"6098_CR61","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.cell.2015.08.063","volume":"163","author":"Y Wang","year":"2015","unstructured":"Wang Y, Zhang T, Kwiatkowski N, Abraham BJ, Lee TI, Xie S, et al. CDK7-dependent transcriptional addiction in triple-negative breast cancer. Cell. 2015;163(1):174\u201386.","journal-title":"Cell"},{"key":"6098_CR62","volume-title":"Coactivator condensation at super-enhancers links phase separation and gene control","author":"BR Sabari","year":"2018","unstructured":"Sabari BR, Dall\u2019Agnese A, Boija A, Klein IA, Coffey EL, Shrinivas K, et al. Coactivator condensation at super-enhancers links phase separation and gene control. Volume 361. New York, NY: Science; 2018. 6400."},{"issue":"5","key":"6098_CR63","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nrm.2017.7","volume":"18","author":"SF Banani","year":"2017","unstructured":"Banani SF, Lee HO, Hyman AA, Rosen MK. Biomolecular condensates: organizers of cellular biochemistry. Nat Rev Mol Cell Biol. 2017;18(5):285\u201398.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6098_CR64","volume-title":"Liquid phase condensation in cell physiology and disease","author":"Y Shin","year":"2017","unstructured":"Shin Y, Brangwynne CP. Liquid phase condensation in cell physiology and disease. Volume 357. New York, NY: Science; 2017. 6357."},{"issue":"7","key":"6098_CR65","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1016\/j.cell.2018.10.042","volume":"175","author":"A Boija","year":"2018","unstructured":"Boija A, Klein IA, Sabari BR, Dall\u2019Agnese A, Coffey EL, Zamudio AV, et al. Transcription factors activate genes through the phase-separation capacity of their activation domains. Cell. 2018;175(7):1842\u2013e5516.","journal-title":"Cell"},{"issue":"2","key":"6098_CR66","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.cell.2023.12.005","volume":"187","author":"M Du","year":"2024","unstructured":"Du M, Stitzinger SH, Spille JH, Cho WK, Lee C, Hijaz M, et al. Direct observation of a condensate effect on super-enhancer controlled gene bursting. Cell. 2024;187(2):331\u2013. \u2013\u200944.e17.","journal-title":"Cell"},{"issue":"10","key":"6098_CR67","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/s41594-024-01322-6","volume":"31","author":"J Yang","year":"2024","unstructured":"Yang J, Chung CI, Koach J, Liu H, Navalkar A, He H, et al. MYC phase separation selectively modulates the transcriptome. Nat Struct Mol Biol. 2024;31(10):1567\u201379.","journal-title":"Nat Struct Mol Biol"},{"issue":"8","key":"6098_CR68","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1016\/j.ymthe.2021.03.024","volume":"29","author":"M Zhang","year":"2021","unstructured":"Zhang M, Hoyle RG, Ma Z, Sun B, Cai W, Cai H, et al. FOSL1 promotes metastasis of head and neck squamous cell carcinoma through super-enhancer-driven transcription program. Mol Therapy: J Am Soc Gene Therapy. 2021;29(8):2583\u2013600.","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"issue":"1","key":"6098_CR69","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1038\/s41467-021-24137-1","volume":"12","author":"J Dong","year":"2021","unstructured":"Dong J, Li J, Li Y, Ma Z, Yu Y, Wang CY. Transcriptional super-enhancers control cancer stemness and metastasis genes in squamous cell carcinoma. Nat Commun. 2021;12(1):3974.","journal-title":"Nat Commun"},{"issue":"1","key":"6098_CR70","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s13046-021-02129-9","volume":"40","author":"E Bian","year":"2021","unstructured":"Bian E, Chen X, Cheng L, Cheng M, Chen Z, Yue X, et al. Super-enhancer-associated TMEM44-AS1 aggravated glioma progression by forming a positive feedback loop with Myc. J Experimental Clin cancer Research: CR. 2021;40(1):337.","journal-title":"J Experimental Clin cancer Research: CR"},{"issue":"1","key":"6098_CR71","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1038\/s41467-021-22445-0","volume":"12","author":"H Huang","year":"2021","unstructured":"Huang H, Hu J, Maryam A, Huang Q, Zhang Y, Ramakrishnan S, et al. Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling. Nat Commun. 2021;12(1):2242.","journal-title":"Nat Commun"},{"issue":"18","key":"6098_CR72","doi-asserted-by":"publisher","first-page":"10230","DOI":"10.1093\/nar\/gkac778","volume":"50","author":"ZZ Zheng","year":"2022","unstructured":"Zheng ZZ, Xia L, Hu GS, Liu JY, Hu YH, Chen YJ, et al. Super-enhancer-controlled positive feedback loop BRD4\/ER\u03b1-RET-ER\u03b1 promotes ER\u03b1-positive breast cancer. Nucleic Acids Res. 2022;50(18):10230\u201348.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"6098_CR73","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13058-021-01479-8","volume":"23","author":"AS Ropri","year":"2021","unstructured":"Ropri AS, DeVaux RS, Eng J, Chittur SV, Herschkowitz JI. Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer. Breast cancer Research: BCR. 2021;23(1):101.","journal-title":"Breast cancer Research: BCR"},{"issue":"11","key":"6098_CR74","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1016\/j.celrep.2019.10.093","volume":"29","author":"Y Xu","year":"2019","unstructured":"Xu Y, Wu Y, Zhang S, Ma P, Jin X, Wang Z, et al. A tumor-specific Super-enhancer drives Immune Evasion by Guiding Synchronous expression of PD-L1 and PD-L2. Cell Rep. 2019;29(11):3435\u2013e474.","journal-title":"Cell Rep"},{"issue":"7920","key":"6098_CR75","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/s41586-022-04906-8","volume":"607","author":"E Bal","year":"2022","unstructured":"Bal E, Kumar R, Hadigol M, Holmes AB, Hilton LK, Loh JW, et al. Super-enhancer hypermutation alters oncogene expression in B cell lymphoma. Nature. 2022;607(7920):808\u201315.","journal-title":"Nature"},{"issue":"1","key":"6098_CR76","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s13046-022-02428-9","volume":"41","author":"F Fang","year":"2022","unstructured":"Fang F, Lu J, Sang X, Tao YF, Wang JW, Zhang ZM, et al. Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia. J Experimental Clin cancer Research: CR. 2022;41(1):225.","journal-title":"J Experimental Clin cancer Research: CR"},{"issue":"3","key":"6098_CR77","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/0008-5472.CAN-21-0921","volume":"82","author":"Y Jia","year":"2022","unstructured":"Jia Y, Zhou J, Tan TK, Chung TH, Chen Y, Chooi JY, et al. Super enhancer-mediated Upregulation of HJURP promotes growth and survival of t(4;14)-Positive multiple myeloma. Cancer Res. 2022;82(3):406\u201318.","journal-title":"Cancer Res"},{"issue":"1","key":"6098_CR78","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12943-023-01767-1","volume":"22","author":"J Zhou","year":"2023","unstructured":"Zhou J, Toh SH, Tan TK, Balan K, Lim JQ, Tan TZ, et al. Super-enhancer-driven TOX2 mediates oncogenesis in natural Killer\/T cell lymphoma. Mol Cancer. 2023;22(1):69.","journal-title":"Mol Cancer"},{"key":"6098_CR79","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.omtn.2021.10.028","volume":"26","author":"W Liang","year":"2021","unstructured":"Liang W, Shi C, Hong W, Li P, Zhou X, Fu W, et al. Super-enhancer-driven lncRNA-DAW promotes liver cancer cell proliferation through activation of Wnt\/\u03b2-catenin pathway. Mol Therapy Nucleic Acids. 2021;26:1351\u201363.","journal-title":"Mol Therapy Nucleic Acids"},{"key":"6098_CR80","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.canlet.2021.10.039","volume":"525","author":"F Wu","year":"2022","unstructured":"Wu F, Xu L, Tu Y, Cheung OK, Szeto LL, Mok MT, et al. Sirtuin 7 super-enhancer drives epigenomic reprogramming in hepatocarcinogenesis. Cancer Lett. 2022;525:115\u201330.","journal-title":"Cancer Lett"},{"issue":"1","key":"6098_CR81","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1038\/s41467-023-40798-6","volume":"14","author":"CE Antal","year":"2023","unstructured":"Antal CE, Oh TG, Aigner S, Luo EC, Yee BA, Campos T, et al. A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer. Nat Commun. 2023;14(1):5195.","journal-title":"Nat Commun"},{"issue":"10","key":"6098_CR82","doi-asserted-by":"publisher","first-page":"e1087","DOI":"10.1002\/ctm2.1087","volume":"12","author":"W Dai","year":"2022","unstructured":"Dai W, Wu J, Peng X, Hou W, Huang H, Cheng Q, et al. CDK12 orchestrates super-enhancer-associated CCDC137 transcription to direct hepatic metastasis in colorectal cancer. Clin Translational Med. 2022;12(10):e1087.","journal-title":"Clin Translational Med"},{"key":"6098_CR83","doi-asserted-by":"publisher","first-page":"724655","DOI":"10.3389\/fonc.2021.724655","volume":"11","author":"D Yu","year":"2021","unstructured":"Yu D, Yang X, Lin J, Cao Z, Lu C, Yang Z, et al. Super-enhancer Induced IL-20RA promotes Proliferation\/Metastasis and Immune Evasion in Colorectal Cancer. Front Oncol. 2021;11:724655.","journal-title":"Front Oncol"},{"issue":"4","key":"6098_CR84","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ccell.2020.03.005","volume":"37","author":"H Alam","year":"2020","unstructured":"Alam H, Tang M, Maitituoheti M, Dhar SS, Kumar M, Han CY, et al. KMT2D Deficiency impairs super-enhancers to Confer a glycolytic vulnerability in Lung Cancer. Cancer Cell. 2020;37(4):599\u2013e6177.","journal-title":"Cancer Cell"},{"issue":"1","key":"6098_CR85","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13045-022-01331-2","volume":"15","author":"T Zhang","year":"2022","unstructured":"Zhang T, Xia W, Song X, Mao Q, Huang X, Chen B, et al. Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-\u03b2\/SMAD3 pathway. J Hematol Oncol. 2022;15(1):114.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"6098_CR86","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1038\/s41467-022-31919-8","volume":"13","author":"MR Kelly","year":"2022","unstructured":"Kelly MR, Wisniewska K, Regner MJ, Lewis MW, Perreault AA, Davis ES, et al. A multi-omic dissection of super-enhancer driven oncogenic gene expression programs in ovarian cancer. Nat Commun. 2022;13(1):4247.","journal-title":"Nat Commun"},{"issue":"10","key":"6098_CR87","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1158\/0008-5472.CAN-22-2433","volume":"83","author":"M Li","year":"2023","unstructured":"Li M, Liu M, Han W, Wang Z, Han D, Patalano S, et al. LSD1 inhibition disrupts Super-enhancer-driven Oncogenic Transcriptional Programs in Castration-resistant prostate Cancer. Cancer Res. 2023;83(10):1684\u201398.","journal-title":"Cancer Res"},{"key":"6098_CR88","doi-asserted-by":"publisher","first-page":"106940","DOI":"10.1016\/j.phrs.2023.106940","volume":"197","author":"M Tan","year":"2023","unstructured":"Tan M, Pan Q, Gong H, Zhai X, Wan Z, Ge M, et al. Super-enhancer-associated SNHG15 cooperating with FOSL1 contributes to bladder cancer progression through the WNT pathway. Pharmacol Res. 2023;197:106940.","journal-title":"Pharmacol Res"},{"issue":"11","key":"6098_CR89","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1038\/s41375-019-0474-0","volume":"33","author":"Y Ding","year":"2019","unstructured":"Ding Y, Zhang B, Payne JL, Song C, Ge Z, Gowda C, et al. Ikaros tumor suppressor function includes induction of active enhancers and super-enhancers along with pioneering activity. Leukemia. 2019;33(11):2720\u201331.","journal-title":"Leukemia"},{"key":"6098_CR90","doi-asserted-by":"crossref","unstructured":"Liu B, Liu X, Han L, Chen X, Wu X, Wu J et al. BRD4-directed super-enhancer organization of transcription repression programs links to chemotherapeutic efficacy in breast cancer. Proc Natl Acad Sci USA. 2022;119(6).","DOI":"10.1073\/pnas.2109133119"},{"issue":"1","key":"6098_CR91","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12943-020-01236-z","volume":"19","author":"R Deng","year":"2020","unstructured":"Deng R, Huang JH, Wang Y, Zhou LH, Wang ZF, Hu BX, et al. Disruption of super-enhancer-driven tumor suppressor gene RCAN1.4 expression promotes the malignancy of breast carcinoma. Mol Cancer. 2020;19(1):122.","journal-title":"Mol Cancer"},{"issue":"1","key":"6098_CR92","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cell.2012.08.026","volume":"151","author":"CY Lin","year":"2012","unstructured":"Lin CY, Lov\u00e9n J, Rahl PB, Paranal RM, Burge CB, Bradner JE, et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 2012;151(1):56\u201367.","journal-title":"Cell"},{"issue":"1","key":"6098_CR93","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.trecan.2015.07.001","volume":"1","author":"AS Bhagwat","year":"2015","unstructured":"Bhagwat AS, Vakoc CR. Targeting transcription factors in Cancer. Trends cancer. 2015;1(1):53\u201365.","journal-title":"Trends cancer"},{"issue":"19","key":"6098_CR94","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1158\/0008-5472.CAN-19-0442","volume":"79","author":"ZY Qin","year":"2019","unstructured":"Qin ZY, Wang T, Su S, Shen LT, Zhu GX, Liu Q, et al. BRD4 promotes gastric Cancer Progression and Metastasis through Acetylation-Dependent stabilization of snail. Cancer Res. 2019;79(19):4869\u201381.","journal-title":"Cancer Res"},{"issue":"8","key":"6098_CR95","first-page":"1114","volume":"22","author":"C Shi","year":"2020","unstructured":"Shi C, Ye Z, Han J, Ye X, Lu W, Ji C, et al. BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma. Neurooncology. 2020;22(8):1114\u201325.","journal-title":"Neurooncology"},{"issue":"3","key":"6098_CR96","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.cell.2013.07.013","volume":"154","author":"P Anand","year":"2013","unstructured":"Anand P, Brown JD, Lin CY, Qi J, Zhang R, Artero PC, et al. BET bromodomains mediate transcriptional pause release in heart failure. Cell. 2013;154(3):569\u201382.","journal-title":"Cell"},{"issue":"24","key":"6098_CR97","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1161\/CIRCULATIONAHA.120.047239","volume":"142","author":"SY Kim","year":"2020","unstructured":"Kim SY, Zhang X, Schiattarella GG, Altamirano F, Ramos TAR, French KM, et al. Epigenetic reader BRD4 (bromodomain-Containing protein 4) governs nucleus-encoded mitochondrial transcriptome to regulate cardiac function. Circulation. 2020;142(24):2356\u201370.","journal-title":"Circulation"},{"key":"6098_CR98","doi-asserted-by":"publisher","first-page":"112426","DOI":"10.1016\/j.ejmech.2020.112426","volume":"200","author":"D Liang","year":"2020","unstructured":"Liang D, Yu Y, Ma Z. Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery. Eur J Med Chem. 2020;200:112426.","journal-title":"Eur J Med Chem"},{"issue":"10","key":"6098_CR99","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrg3293","volume":"13","author":"K Adelman","year":"2012","unstructured":"Adelman K, Lis JT. Promoter-proximal pausing of RNA polymerase II: emerging roles in metazoans. Nat Rev Genet. 2012;13(10):720\u201331.","journal-title":"Nat Rev Genet"},{"issue":"4","key":"6098_CR100","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.molcel.2015.06.032","volume":"59","author":"KA Nilson","year":"2015","unstructured":"Nilson KA, Guo J, Turek ME, Brogie JE, Delaney E, Luse DS, et al. THZ1 reveals roles for Cdk7 in co-transcriptional capping and pausing. Mol Cell. 2015;59(4):576\u201387.","journal-title":"Mol Cell"},{"issue":"1","key":"6098_CR101","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.celrep.2014.08.055","volume":"9","author":"R Di Micco","year":"2014","unstructured":"Di Micco R, Fontanals-Cirera B, Low V, Ntziachristos P, Yuen SK, Lovell CD, et al. Control of embryonic stem cell identity by BRD4-dependent transcriptional elongation of super-enhancer-associated pluripotency genes. Cell Rep. 2014;9(1):234\u201347.","journal-title":"Cell Rep"},{"issue":"6","key":"6098_CR102","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1128\/MCB.01426-14","volume":"35","author":"K Liang","year":"2015","unstructured":"Liang K, Gao X, Gilmore JM, Florens L, Washburn MP, Smith E, et al. Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing. Mol Cell Biol. 2015;35(6):928\u201338.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"6098_CR103","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nbt.2776","volume":"32","author":"L Anders","year":"2014","unstructured":"Anders L, Guenther MG, Qi J, Fan ZP, Marineau JJ, Rahl PB, et al. Genome-wide localization of small molecules. Nat Biotechnol. 2014;32(1):92\u20136.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"6098_CR104","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904\u201317.","journal-title":"Cell"},{"issue":"7327","key":"6098_CR105","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067\u201373.","journal-title":"Nature"},{"issue":"9","key":"6098_CR106","doi-asserted-by":"publisher","first-page":"107642","DOI":"10.1016\/j.jbc.2024.107642","volume":"300","author":"BD Ormsbee Golden","year":"2024","unstructured":"Ormsbee Golden BD, Gonzalez DV, Yochum GS, Coulter DW, Rizzino A. SOX2 represses c-MYC transcription by altering the co-activator landscape of the c-MYC super-enhancer and promoter regions. J Biol Chem. 2024;300(9):107642.","journal-title":"J Biol Chem"},{"key":"6098_CR107","doi-asserted-by":"publisher","first-page":"217129","DOI":"10.1016\/j.canlet.2024.217129","volume":"608","author":"SK Jaiswal","year":"2025","unstructured":"Jaiswal SK, Fedkenheuer K, Khamar R, Tan H, Gotea V, Raj S, et al. The Megacomplex protects ER-alpha from degradation by Fulvestrant in epithelial ovarian cancer. Cancer Lett. 2025;608:217129.","journal-title":"Cancer Lett"},{"issue":"1","key":"6098_CR108","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12964-024-01599-6","volume":"22","author":"P Song","year":"2024","unstructured":"Song P, Han R, Yang F. Super enhancer lncRNAs: a novel hallmark in cancer. Cell Communication Signaling: CCS. 2024;22(1):207.","journal-title":"Cell Communication Signaling: CCS"},{"issue":"6","key":"6098_CR109","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.cell.2017.02.015","volume":"168","author":"HI Suzuki","year":"2017","unstructured":"Suzuki HI, Young RA, Sharp PA. Super-enhancer-mediated RNA Processing revealed by Integrative MicroRNA Network Analysis. Cell. 2017;168(6):1000\u2013e1415.","journal-title":"Cell"},{"issue":"22","key":"6098_CR110","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1038\/onc.2013.242","volume":"33","author":"B Tolani","year":"2014","unstructured":"Tolani B, Gopalakrishnan R, Punj V, Matta H, Chaudhary PM. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors. Oncogene. 2014;33(22):2928\u201337.","journal-title":"Oncogene"},{"issue":"5","key":"6098_CR111","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.ccell.2016.10.002","volume":"30","author":"M Ceribelli","year":"2016","unstructured":"Ceribelli M, Hou ZE, Kelly PN, Huang DW, Wright G, Ganapathi K, et al. A druggable TCF4- and BRD4-Dependent Transcriptional Network sustains malignancy in Blastic Plasmacytoid dendritic cell neoplasm. Cancer Cell. 2016;30(5):764\u201378.","journal-title":"Cancer Cell"},{"issue":"3","key":"6098_CR112","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.celrep.2016.03.054","volume":"15","author":"AS Bhagwat","year":"2016","unstructured":"Bhagwat AS, Roe JS, Mok BYL, Hohmann AF, Shi J, Vakoc CR. BET bromodomain inhibition releases the Mediator Complex from Select cis-Regulatory Elements. Cell Rep. 2016;15(3):519\u201330.","journal-title":"Cell Rep"},{"issue":"21","key":"6098_CR113","doi-asserted-by":"publisher","first-page":"6320","DOI":"10.1158\/0008-5472.CAN-16-0854","volume":"76","author":"Y Yokoyama","year":"2016","unstructured":"Yokoyama Y, Zhu H, Lee JH, Kossenkov AV, Wu SY, Wickramasinghe JM, et al. BET inhibitors suppress ALDH Activity by Targeting ALDH1A1 Super-enhancer in Ovarian Cancer. Cancer Res. 2016;76(21):6320\u201330.","journal-title":"Cancer Res"},{"issue":"7","key":"6098_CR114","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nsmb.3249","volume":"23","author":"O Gilan","year":"2016","unstructured":"Gilan O, Lam EY, Becher I, Lugo D, Cannizzaro E, Joberty G, et al. Functional interdependence of BRD4 and DOT1L in MLL leukemia. Nat Struct Mol Biol. 2016;23(7):673\u201381.","journal-title":"Nat Struct Mol Biol"},{"key":"6098_CR115","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","volume":"5","author":"JP Copp\u00e9","year":"2010","unstructured":"Copp\u00e9 JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99\u2013118.","journal-title":"Annu Rev Pathol"},{"issue":"6","key":"6098_CR116","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1158\/2159-8290.CD-16-0217","volume":"6","author":"N Tasdemir","year":"2016","unstructured":"Tasdemir N, Banito A, Roe JS, Alonso-Curbelo D, Camiolo M, Tschaharganeh DF, et al. BRD4 connects enhancer remodeling to Senescence Immune Surveillance. Cancer Discov. 2016;6(6):612\u201329.","journal-title":"Cancer Discov"},{"key":"6098_CR117","first-page":"1010","volume-title":"Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells","author":"E Arner","year":"2015","unstructured":"Arner E, Daub CO, Vitting-Seerup K, Andersson R, Lilje B, Drabl\u00f8s F, et al. Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells. Volume 347. New York, NY: Science; 2015. pp. 1010\u20134. 6225."},{"issue":"12","key":"6098_CR118","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/ng.3142","volume":"46","author":"LJ Core","year":"2014","unstructured":"Core LJ, Martins AL, Danko CG, Waters CT, Siepel A, Lis JT. Analysis of nascent RNA identifies a unified architecture of initiation regions at mammalian promoters and enhancers. Nat Genet. 2014;46(12):1311\u201320.","journal-title":"Nat Genet"},{"issue":"10","key":"6098_CR119","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/nchembio.2166","volume":"12","author":"T Zhang","year":"2016","unstructured":"Zhang T, Kwiatkowski N, Olson CM, Dixon-Clarke SE, Abraham BJ, Greifenberg AK, et al. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol. 2016;12(10):876\u201384.","journal-title":"Nat Chem Biol"},{"issue":"7572","key":"6098_CR120","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nature14904","volume":"526","author":"HE Pelish","year":"2015","unstructured":"Pelish HE, Liau BB, Nitulescu II, Tangpeerachaikul A, Poss ZC, Da Silva DH, et al. Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Nature. 2015;526(7572):273\u20136.","journal-title":"Nature"},{"key":"6098_CR121","doi-asserted-by":"crossref","unstructured":"Clarke PA, Ortiz-Ruiz MJ, TePoele R, Adeniji-Popoola O, Box G, Court W et al. Assessing the mechanism and therapeutic potential of modulators of the human mediator complex-associated protein kinases. eLife. 2016;5.","DOI":"10.7554\/eLife.20722"},{"issue":"30","key":"6098_CR122","doi-asserted-by":"publisher","first-page":"30178","DOI":"10.18632\/oncotarget.4903","volume":"6","author":"AL Kennedy","year":"2015","unstructured":"Kennedy AL, Vallurupalli M, Chen L, Crompton B, Cowley G, Vazquez F, et al. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1\/CDK4 pathway inhibition in ewing sarcoma. Oncotarget. 2015;6(30):30178\u201393.","journal-title":"Oncotarget"},{"issue":"13","key":"6098_CR123","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1158\/0008-5472.CAN-17-2949","volume":"78","author":"AA Mohamed","year":"2018","unstructured":"Mohamed AA, Xavier CP, Sukumar G, Tan SH, Ravindranath L, Seraj N, et al. Identification of a small molecule that selectively inhibits ERG-Positive Cancer cell growth. Cancer Res. 2018;78(13):3659\u201371.","journal-title":"Cancer Res"},{"issue":"7","key":"6098_CR124","first-page":"3385","volume":"37","author":"B Winters","year":"2017","unstructured":"Winters B, Brown L, Coleman I, Nguyen H, Minas TZ, Kollath L, et al. Inhibition of ERG activity in patient-derived prostate Cancer xenografts by YK-4-279. Anticancer Res. 2017;37(7):3385\u201396.","journal-title":"Anticancer Res"},{"issue":"1","key":"6098_CR125","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1038\/s41467-021-24687-4","volume":"12","author":"W Wang","year":"2021","unstructured":"Wang W, Tang YA, Xiao Q, Lee WC, Cheng B, Niu Z, et al. Stromal induction of BRD4 phosphorylation results in chromatin remodeling and BET inhibitor resistance in Colorectal Cancer. Nat Commun. 2021;12(1):4441.","journal-title":"Nat Commun"},{"key":"6098_CR126","doi-asserted-by":"crossref","unstructured":"Guo J, Liu Y, Lv J, Zou B, Chen Z, Li K et al. BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors. J Clin Investig. 2021;131(1).","DOI":"10.1172\/JCI133090"},{"issue":"8","key":"6098_CR127","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1158\/1078-0432.CCR-16-0453","volume":"23","author":"Y Ma","year":"2017","unstructured":"Ma Y, Wang L, Neitzel LR, Loganathan SN, Tang N, Qin L, et al. The MAPK pathway regulates intrinsic resistance to BET inhibitors in Colorectal Cancer. Clin cancer Research: Official J Am Association Cancer Res. 2017;23(8):2027\u201337.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"7586","key":"6098_CR128","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nature16863","volume":"529","author":"J Settleman","year":"2016","unstructured":"Settleman J. Cancer: bet on drug resistance. Nature. 2016;529(7586):289\u201390.","journal-title":"Nature"},{"issue":"4","key":"6098_CR129","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1172\/JCI126327","volume":"130","author":"L Wang","year":"2020","unstructured":"Wang L, Xu M, Kao CY, Tsai SY, Tsai MJ. Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1. J Clin Investig. 2020;130(4):1782\u201392.","journal-title":"J Clin Investig"},{"issue":"9","key":"6098_CR130","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/nm.4372","volume":"23","author":"H Janouskova","year":"2017","unstructured":"Janouskova H, El Tekle G, Bellini E, Udeshi ND, Rinaldi A, Ulbricht A, et al. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nat Med. 2017;23(9):1046\u201354.","journal-title":"Nat Med"},{"issue":"24","key":"6098_CR131","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1080\/15384101.2017.1388973","volume":"16","author":"X Dai","year":"2017","unstructured":"Dai X, Wang Z, Wei W. SPOP-mediated degradation of BRD4 dictates cellular sensitivity to BET inhibitors. Cell Cycle (Georgetown Tex). 2017;16(24):2326\u20139.","journal-title":"Cell Cycle (Georgetown Tex)"},{"issue":"9","key":"6098_CR132","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/nm.4378","volume":"23","author":"X Dai","year":"2017","unstructured":"Dai X, Gan W, Li X, Wang S, Zhang W, Huang L, et al. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat Med. 2017;23(9):1063\u201371.","journal-title":"Nat Med"},{"issue":"10","key":"6098_CR133","first-page":"574","volume":"17","author":"CA Bradley","year":"2017","unstructured":"Bradley CA. Prostate cancer: BET inhibitors - SPOP right there! Nat Rev Cancer. 2017;17(10):574\u20135.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"6098_CR134","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/nm.4379","volume":"23","author":"P Zhang","year":"2017","unstructured":"Zhang P, Wang D, Zhao Y, Ren S, Gao K, Ye Z, et al. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nat Med. 2017;23(9):1055\u201362.","journal-title":"Nat Med"},{"issue":"32","key":"6098_CR135","doi-asserted-by":"publisher","first-page":"33623","DOI":"10.18632\/oncotarget.5601","volume":"6","author":"G Borbely","year":"2015","unstructured":"Borbely G, Haldosen LA, Dahlman-Wright K, Zhao C. Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells. Oncotarget. 2015;6(32):33623\u201335.","journal-title":"Oncotarget"},{"issue":"5","key":"6098_CR136","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/1535-7163.MCT-13-0770","volume":"13","author":"W Fiskus","year":"2014","unstructured":"Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, et al. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther. 2014;13(5):1142\u201354.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"6098_CR137","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41467-020-20378-8","volume":"12","author":"AL Latif","year":"2021","unstructured":"Latif AL, Newcombe A, Li S, Gilroy K, Robertson NA, Lei X, et al. BRD4-mediated repression of p53 is a target for combination therapy in AML. Nat Commun. 2021;12(1):241.","journal-title":"Nat Commun"},{"issue":"10","key":"6098_CR138","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/nm.3952","volume":"21","author":"PK Mazur","year":"2015","unstructured":"Mazur PK, Herner A, Mello SS, Wirth M, Hausmann S, S\u00e1nchez-Rivera FJ, et al. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat Med. 2015;21(10):1163\u201371.","journal-title":"Nat Med"},{"issue":"10","key":"6098_CR139","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1158\/1078-0432.CCR-15-1666","volume":"22","author":"J Shahbazi","year":"2016","unstructured":"Shahbazi J, Liu PY, Atmadibrata B, Bradner JE, Marshall GM, Lock RB, et al. The bromodomain inhibitor JQ1 and the histone deacetylase inhibitor panobinostat synergistically reduce N-Myc expression and induce Anticancer effects. Clin cancer Research: Official J Am Association Cancer Res. 2016;22(10):2534\u201344.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"1","key":"6098_CR140","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.neo.2018.11.006","volume":"21","author":"L Zhao","year":"2019","unstructured":"Zhao L, Okhovat JP, Hong EK, Kim YH, Wood GS. Preclinical studies support combined inhibition of BET Family Proteins and Histone Deacetylases as epigenetic therapy for cutaneous T-Cell lymphoma. Neoplasia (New York NY). 2019;21(1):82\u201392.","journal-title":"Neoplasia (New York NY)"},{"issue":"5","key":"6098_CR141","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1158\/1078-0432.CCR-20-3044","volume":"27","author":"J Chen","year":"2021","unstructured":"Chen J, Nelson C, Wong M, Tee AE, Liu PY, La T, et al. Targeted therapy of TERT-Rearranged neuroblastoma with BET Bromodomain Inhibitor and proteasome inhibitor combination therapy. Clin cancer Research: Official J Am Association Cancer Res. 2021;27(5):1438\u201351.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"8","key":"6098_CR142","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1158\/1535-7163.MCT-16-0459","volume":"16","author":"LT Lam","year":"2017","unstructured":"Lam LT, Lin X, Faivre EJ, Yang Z, Huang X, Wilcox DM, et al. Vulnerability of small-cell lung Cancer to apoptosis Induced by the combination of BET Bromodomain Proteins and BCL2 inhibitors. Mol Cancer Ther. 2017;16(8):1511\u201320.","journal-title":"Mol Cancer Ther"},{"key":"6098_CR143","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.canlet.2019.11.027","volume":"469","author":"W Zhang","year":"2020","unstructured":"Zhang W, Ge H, Jiang Y, Huang R, Wu Y, Wang D, et al. Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma. Cancer Lett. 2020;469:510\u201323.","journal-title":"Cancer Lett"},{"issue":"10","key":"6098_CR144","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1016\/j.ymthe.2021.05.019","volume":"29","author":"L Xia","year":"2021","unstructured":"Xia L, Liu JY, Zheng ZZ, Chen YJ, Ding JC, Hu YH, et al. BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma. Mol Therapy: J Am Soc Gene Therapy. 2021;29(10):3011\u201326.","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"issue":"12","key":"6098_CR145","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1016\/j.celrep.2017.11.095","volume":"21","author":"S Karakashev","year":"2017","unstructured":"Karakashev S, Zhu H, Yokoyama Y, Zhao B, Fatkhutdinov N, Kossenkov AV, et al. BET bromodomain inhibition synergizes with PARP inhibitor in epithelial ovarian Cancer. Cell Rep. 2017;21(12):3398\u2013405.","journal-title":"Cell Rep"},{"key":"6098_CR146","doi-asserted-by":"crossref","unstructured":"Yang L, Zhang Y, Shan W, Hu Z, Yuan J, Pi J et al. Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci Transl Med. 2017;9(400).","DOI":"10.1126\/scitranslmed.aal1645"},{"key":"6098_CR147","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ebiom.2019.05.035","volume":"44","author":"AL Miller","year":"2019","unstructured":"Miller AL, Fehling SC, Garcia PL, Gamblin TL, Council LN, van Waardenburg R, et al. The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors. EBioMedicine. 2019;44:419\u201330.","journal-title":"EBioMedicine"},{"key":"6098_CR148","doi-asserted-by":"publisher","first-page":"114116","DOI":"10.1016\/j.ejmech.2022.114116","volume":"230","author":"SH Huang","year":"2022","unstructured":"Huang SH, Cao R, Lin QW, Wu SQ, Gao LL, Sun Q, et al. Design, synthesis and mechanism studies of novel dual PARP1\/BRD4 inhibitors against pancreatic cancer. Eur J Med Chem. 2022;230:114116.","journal-title":"Eur J Med Chem"},{"issue":"19","key":"6098_CR149","doi-asserted-by":"publisher","first-page":"7725","DOI":"10.1021\/acs.jcim.4c01421","volume":"64","author":"B Feng","year":"2024","unstructured":"Feng B, Yu H, Dong X, D\u00edaz-Holgu\u00edn A, Antolin AA, Hu H. Combining Data-Driven and structure-based approaches in Designing Dual PARP1-BRD4 inhibitors for breast Cancer Treatment. J Chem Inf Model. 2024;64(19):7725\u201342.","journal-title":"J Chem Inf Model"},{"issue":"9","key":"6098_CR150","doi-asserted-by":"publisher","first-page":"6803","DOI":"10.1021\/acs.jmedchem.2c00135","volume":"65","author":"J Zhang","year":"2022","unstructured":"Zhang J, Yang C, Tang P, Chen J, Zhang D, Li Y, et al. Discovery of 4-Hydroxyquinazoline derivatives as small molecular BET\/PARP1 inhibitors that induce defective homologous recombination and lead to synthetic lethality for triple-negative breast Cancer Therapy. J Med Chem. 2022;65(9):6803\u201325.","journal-title":"J Med Chem"},{"issue":"3","key":"6098_CR151","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discovery. 2022;21(3):181\u2013200.","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"6098_CR152","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13045-021-01146-7","volume":"14","author":"H Li","year":"2021","unstructured":"Li H, Dong J, Cai M, Xu Z, Cheng XD, Qin JJ. Protein degradation technology: a strategic paradigm shift in drug discovery. J Hematol Oncol. 2021;14(1):138.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"6098_CR153","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1080\/13543776.2024.2400166","volume":"34","author":"Z Ma","year":"2024","unstructured":"Ma Z, Zhang C, Bolinger AA, Zhou J. An updated patent review of BRD4 degraders. Expert Opin Ther Pat. 2024;34(10):929\u201351.","journal-title":"Expert Opin Ther Pat"},{"issue":"8002","key":"6098_CR154","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41586-024-07089-6","volume":"627","author":"O Hsia","year":"2024","unstructured":"Hsia O, Hinterndorfer M, Cowan AD, Iso K, Ishida T, Sundaramoorthy R, et al. Targeted protein degradation via intramolecular bivalent glues. Nature. 2024;627(8002):204\u201311.","journal-title":"Nature"},{"issue":"9","key":"6098_CR155","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/ajh.27385","volume":"99","author":"K Bauer","year":"2024","unstructured":"Bauer K, Hauswirth A, Gleixner KV, Greiner G, Thaler J, Bettelheim P, et al. BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL. Am J Hematol. 2024;99(9):1721\u201331.","journal-title":"Am J Hematol"},{"issue":"1","key":"6098_CR156","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41420-023-01775-6","volume":"9","author":"H Qian","year":"2023","unstructured":"Qian H, Zhu M, Tan X, Zhang Y, Liu X, Yang L. Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targets. Cell Death Discovery. 2023;9(1):470.","journal-title":"Cell Death Discovery"},{"issue":"17","key":"6098_CR157","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1016\/j.cell.2024.06.012","volume":"187","author":"J Yu","year":"2024","unstructured":"Yu J, Yan Y, Li S, Xu Y, Parolia A, Rizvi S, et al. Progestogen-driven B7-H4 contributes to onco-fetal immune tolerance. Cell. 2024;187(17):4713\u2013e3219.","journal-title":"Cell"},{"issue":"7","key":"6098_CR158","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/j.cell.2024.02.022","volume":"187","author":"D Jia","year":"2024","unstructured":"Jia D, Wang Q, Qi Y, Jiang Y, He J, Lin Y, et al. Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer. Cell. 2024;187(7):1651\u2013e6521.","journal-title":"Cell"},{"issue":"16","key":"6098_CR159","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1158\/0008-5472.CAN-23-3306","volume":"84","author":"Y Sui","year":"2024","unstructured":"Sui Y, Wang T, Mei Y, Zhu Y, Jiang W, Shen J, et al. Targeting Super-enhancer-driven Transcriptional dependencies suppresses aberrant hedgehog pathway activation and overcomes smoothened inhibitor resistance. Cancer Res. 2024;84(16):2690\u2013706.","journal-title":"Cancer Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06098-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06098-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06098-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T14:17:50Z","timestamp":1737469070000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06098-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":159,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6098"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06098-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"26 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that they have no conflicts of interest pertaining to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}